Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade.
Chemistry World May 21, 2013 Emma Stoye	B-vitamins may delay Alzheimer's onset UK researchers have found that high doses of B-vitamins -- including folic acid, vitamin B12 and vitamin B6 -- can slow down brain tissue atrophy, a wasting process associated with Alzheimer's disease.
Chemistry World July 20, 2012 Michael Parkin	New supramolecular Alzheimer's drugs Supramolecular chemistry could provide a new avenue in the treatment of Alzheimer's disease, say scientists in China.
The Motley Fool February 8, 2005 Charly Travers	Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company
AskMen.com Jacob Franek	Alzheimer's Disease 101 It's only in the last decade or so that we have truly come to understand the various disorders of the brain that are associated with age and, in most cases, Alzheimer's disease is the prime suspect. Read on for some basic information.
Chemistry World August 24, 2012 Andrew Turley	Alzheimer's drug flops in Phase III A previously promising drug candidate for the treatment of Alzheimer's disease, solanezumab from Eli Lilly, has delivered disappointing results in Phase III trials.
Managed Care December 2005 David S. Geldmacher	The Cost Benefit to Health Plans of Pharmacotherapy for Alzheimer's Disease As with other chronic diseases of aging, early diagnosis and pharmacologic therapy may reduce the costs for enrollees with Alzheimer's disease. This article reviews patient and caregiver outcomes associated with reduced health care costs and their implications for Managed Care Organizations.
Chemistry World July 22, 2009 Phil Taylor	New drug turns Alzheimer's theory on its head Researchers have been left puzzled by data showing that the antihistamine dimebolin, a drug with promising activity in improving Alzheimer's symptoms, actually seems to increase levels of the toxic protein beta amyloid.
Chemistry World October 14, 2009 Phil Taylor	Tracing amyloid in Alzheimer's A diagnostic compound that allows researchers to look into the brains of Alzheimer's patients will be used for the first time to gauge the effects of an experimental therapy for the disease.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
Chemistry World September 2009	Column: In the pipeline What's the most difficult therapeutic area for drug discovery? They're certainly not all created equal - or if they were, they have definitely diverged since then. The question can be narrowed down quite a bit.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
Chemistry World September 21, 2006 Michael Gross	Alzheimer's Alphabet Alzheimer's researchers are now closer to understanding the natural function of one of the two enzymes that cut A out of APP, and have recreated the process by which fibril formation begins in vivo.
Nurse Practitioner August 2011 Davis et al.	Supportive approaches for Alzheimer Disease Alzheimer disease accounts for almost 80% of all dementia diagnoses. Currently, more than 5 million Americans suffer from this debilitating illness, with the highest prevalence in the oldest age groups.
The Motley Fool January 12, 2005 Charly Travers	Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity.
Chemistry World January 3, 2007 Victoria Gill	Alzheimer's Protein Fingerprint Alzheimer's disease, a debilitating neurodegenerative disorder that eventually results in wasting of the whole brain, offers a chemical clue that should make it easier to spot and possibly easier to treat.
The Motley Fool October 10, 2011 Frank Vinluan	TRGT Tries Again With Alzheimer's Disease Drug Candidate A Targacept compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca has started in mid-stage clinical studies as a potential new Alzheimer's disease treatment.
American Family Physician October 1, 2003 Vincent W. Delagarza	Pharmacologic Treatment of Alzheimer's Disease: An Update Alzheimer's disease is characterized by the development of senile plaques and neurofibrillary tangles, which are associated with neuronal destruction, particularly in cholinergic neurons. Drugs that inhibit the degradation of acetylcholine within synapses are the mainstay of therapy.
The Motley Fool March 17, 2006 Rich Duprey	Eisai's Dementia Problems Clinical trials for expanded use of the Japanese pharma's top-selling drug reveal higher incidences of death. Aricept is already approved for vascular dementia in several countries, but it would seem that FDA approval for use here won't be coming any time soon. Investors, take note.
American Family Physician March 15, 2004	STEPS Memantine (namenda) for moderate to severe alzheimer's disease
The Motley Fool December 28, 2010 Brian Orelli	No Guts, No Glory For better or worse, Elan gains full control of Alzheimer's drug ELND005.
Chemistry World January 30, 2012 James Urquhart	Iron accumulation linked to neurogenerative disease Parkinson's and Alzheimer's could be caused by an accumulation of iron in regions of the brain, Australian researchers say.
Fast Company December 2009 Erica Westly	The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness.
AskMen.com Jacob Franek	Future Cures Almost every disease known to man is under constant research and we can hardly go a day without hearing about some advancement or another. Here are a few diseases for which future cures could be looming on the horizon.
Chemistry World July 30, 2008 Sarah Houlton	A metal trap to stop Alzheimer's Trapping metals could prove a key to curing Alzheimer's disease, according to the promising results of early clinical trials on a compound called PBT2.
Chemistry World March 23, 2010 Sarah Houlton	Microbes implicated in Alzheimer's Microbes such as Candida albicans may be triggering the immune system to release beta amyloid
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
BusinessWeek July 15, 2010 Lopatto & Matsuyama	The Race for Diagnostic Tests for Alzheimer's GE, Bayer, and Avid are vying to be first to market an early test for Alzheimer's.
Chemistry World June 2011	Breaking through the barrier Getting drug molecules into the brain means crossing the defensive blood-brain barrier. Anthony King investigates how chemists are infiltrating the brain's fortress
The Motley Fool May 16, 2007 Mike Havrilla	Waiting on Memory Pharmaceuticals The small-cap biotech is testing a treatment for Alzheimer's, but investors should stand by.
Chemistry World February 7, 2011 Carl Saxton	Targeting memory loss A new treatment for Alzheimer's disease has been developed by Canadian and US scientists.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
Pharmaceutical Executive November 1, 2014 Josh Baxt	2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies.
BusinessWeek January 8, 2007 Catherine Arnst	Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure.
Bio-IT World May 2006 Kevin Davies	Personalized Medicine's Rosy Picture GlaxoSmithKline's head of genetics research, Allen Roses, says that pharmacogenetics is having a profound impact on the stratifying of patients, the minimization of adverse events, and the expedited passage of drug candidates through clinical trials.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool June 18, 2008 Brian Lawler	Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive.
Chemistry World August 24, 2006 Jessica Ebert	Alzheimer's Researchers Tackle Waste Disposal The memory of mice with Alzheimer's-like symptoms is improved by inoculating the mice with an enzyme involved in protein degradation, report US researchers. The work could lead to new therapies for patients with Alzheimer's disease.
Chemistry World October 15, 2013 Dinsa Sachan	Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed.
Chemistry World August 9, 2012	Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials.
Pharmaceutical Executive October 1, 2006 Clinton & Koroneos	Learn & Confirm At Wyeth, a sweeping set of initiatives is transforming the R&D operation - and spotlighting a possible future for drug development.
Chemistry World December 21, 2006 Tom Westgate	Molecular Probe Identifies Patients at Risk of Alzheimer's A new molecule could provide an early warning system for Alzheimer's disease, US researchers hope.
Pharmaceutical Executive May 1, 2009	The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game.
Bio-IT World April 2006 Kevin Davies	Putting the IT in Clinical Trials A new report says that the clinical trials process must be reinvented to reverse the output decline of the pharmaceutical industry and meet the needs of its patients. That reinvention will be shaped by major advances in information technology.
Registered Rep. August 30, 2011 Amy Burroughs	When Your Client Has Alzheimer's One early sign of the disease is trouble managing money, which puts financial advisors on the front lines.
The Motley Fool September 2, 2005 Rich Duprey	An Opportunity Not to Forget Japanese pharmaceutical Eisai targets another segment of the growing Alzheimer's market. Investors, take note.
Chemistry World March 4, 2011 Russell Johnson	Tracking the early stages of Alzheimer's disease UK researchers can track the early steps of formation of peptide clumps linked to Alzheimer's disease using the peptide's fluorescent ability. This could help design effective therapies for the disease at an early stage.